CJC-1295 + Ipamorelin
GHRH analog + GHSR agonist blend
A vendor blend combining two experimental secretagogues. Component evidence does not establish safety or efficacy of the mixture.
Mechanism
Dual upstream stimulation of GH secretion through different receptors
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Human evidence is absent, limited or not confirmatory
Anecdotal schedules are excluded because frequency of online repetition does not establish identity, safety, or a clinically meaningful dose.
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Common bedtime blend schedule | 100/100–200/200 mcg | One administration/day | Once daily | Bedtime, often fasted | Subcutaneous | Community-reported |
| Divided blend schedule | 100/100 mcg | 200/200 mcg/day | Twice daily | Morning fasted and bedtime | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Vendor blend ratios and total vial strengths vary. Component-specific concentrations must be known before any meaningful calculation can be made.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
Vendor blend ratios and total vial strengths vary. Component-specific concentrations must be known before any meaningful calculation can be made.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
No validated blend protocol, interaction profile or long-term safety evidence has been established.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.